BDH INDUSTRIES LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 337 INR | -2.60% |
|
-11.84% | +53.74% |
| May. 18 | BDH Industries Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 | CI |
| Mar. 30 | BDH Industries Limited Announces Directorate Changes | CI |
| Sales 2022 | 694M 8.35M | Sales 2023 | 745M 8.96M | Capitalization | 649M 7.81M |
|---|---|---|---|---|---|
| Net income 2022 | 72M 866K | Net income 2023 | 82M 986K | EV / Sales 2022 | 0.87 x |
| Net cash position 2022 | 166M 1.99M | Net cash position 2023 | 211M 2.54M | EV / Sales 2023 | 0.59 x |
| P/E ratio 2022 |
10.7
x | P/E ratio 2023 |
7.92
x | Employees | 116 |
| Yield 2022 |
2.69% | Yield 2023 |
3.55% | Free-Float | 40.08% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.60% | ||
| 1 week | -11.84% | ||
| Current month | -2.60% | ||
| 1 month | +0.73% | ||
| 3 months | +6.29% | ||
| 6 months | +74.79% | ||
| Current year | +53.74% |
1 week
334.00
397.50
1 month
328.25397.50
Current year
226.20397.50
1 year
142.15397.50
3 years
92.50397.50
5 years
47.05397.50
10 years
25.05397.50
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 68 | 89-12-31 | |
| Chief Executive Officer | 80 | 09-03-31 | |
Nikita Phatak
CMP | Compliance Officer | - | 08-08-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 80 | 09-03-31 | |
| Chief Executive Officer | 68 | 89-12-31 | |
Karthika Nair
BRD | Director/Board Member | 55 | 98-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-03 | 337 | -2.60% | 2 770 |
| 24-05-31 | 346 | -1.70% | 2,398 |
| 24-05-30 | 352 | -2.43% | 2,180 |
| 24-05-29 | 360.8 | -3.86% | 5,357 |
| 24-05-28 | 375.2 | -1.83% | 10,392 |
Delayed Quote Bombay S.E., June 03, 2024 at 04:38 am EDT
More quotes
BDH Industries Limited is engaged in the manufacturing of pharmaceuticals. The Company is also involved in the manufacturing of therapeutic formulations covering a range of pharmaceuticals. Its products include Analgesics, Antacids, Antibacterial, Anticoagulants, Anticonvulsants, Anti-emetics, Antifungals, Antihelmentinics, Antiasthmatic, Antimalarials, Antipsychotics and others. Its products include formulations, such as Fentanyl Citrate Injection USP, KALPANJAN Forte Pain Balm, Compound Magnesium Trisilicate Tablets BP, Alcoholic Iodine Solition BP, COLD Syrup, Dicyclomine Hydrochloride Injection, and Aciclovir Cream BP. Its manufacturing facilities consist of Oncology Division and General Pharmaceuticals. Its specialty formulations include Morphine Sulphate Slow-Release Tablets 15mg, Sulfasalazine Delayed release tablets U.S.P. 500mg, Indomethacin Extended-Release Capsules U.S.P. 75 mg and others. Its manufacturing facility is located in Mumbai.
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q1 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +53.74% | 23.87M | |
| +16.14% | 41.97B | |
| +22.56% | 22.34B | |
| +15.93% | 15.25B | |
| +16.31% | 14B | |
| +49.15% | 12.06B | |
| -10.77% | 6.8B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +14.18% | 5.49B |
- Stock Market
- Equities
- BDH6 Stock
